Expert Interview
Discussing the recent FDA Approval of Relyvrio (AMX0035) for treatment of adults with amyotrophic lateral sclerosis (ALS)
Ticker(s): AMLXInstitution: UCSF
- Assistant professor of neuromuscular medicine at the University of California, San Francisco.
- Currently manages ~20 patients with ALS.
- Research focuses on neuromuscular diseases, ALS, and health equity research; Principal Investigator for various clinical ALS therapy trials.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
